Zai Lab On Regulatory Reforms And Effective Partnering In China
Zai Lab's VP and Head of Business Development Jonathan Wang tells Brain Yang how the China FDA's regulatory reforms make China attractive to international biotechs, and that therapeutic areas such as oncology and anti-infectives are to benefit, along with partnering in China.
You may also be interested in...
How China Regulatory Reforms Ring In International Biotechs' New Year
Just how much regulatory reforms help fuel biotech investment rush in China? Look no further than active deal flow and hot cash rolling in. The new regulations are all about bringing efficiency to their investment in China, industry insiders say.
China Looms Large Seeking New Funding, Deals At J.P. Morgan
Chinese biotech companies are raising their profile and increasing their appeals to investors and partners at the J.P. Morgan Healthcare Conference. After billions in investment and increased activity in M&As, China is likely to remain attractive for international companies large and small vying for a slice of investment or pursuing innovative therapies.
Zai Lab Soars On Nasdaq Debut
Shanghai-based drug developer Zai Lab shares jumped on its first day of public trading, reflecting the strong interest in drug development in China.